Intrauterine Balloon Tamponade May Cut Invasive Procedures

Share this content:
Intrauterine Balloon Tamponade May Cut Invasive Procedures
Intrauterine Balloon Tamponade May Cut Invasive Procedures

WEDNESDAY, Dec. 27, 2017 (HealthDay News) -- For women undergoing vaginal delivery, the use of intrauterine balloon tamponade is associated with a significantly lower use of invasive procedures for hemorrhage control, according to a study published online Dec. 4 in Obstetrics & Gynecology.

Mathilde Revert, from Versailles Saint Quentin University in France, and colleagues assessed rates of invasive procedures for hemorrhage control among 72,529 women delivering between 2011 and 2012 in two French perinatal networks: a pilot in which balloon tamponade was used and a control network.

The researchers found that invasive procedures were used in 298 women, representing 4.1 per 1,000 deliveries. The pilot network had a significantly lower proportion of women with at least one invasive procedure (3 versus 5.1/1,000). The pilot network also had significantly lower use of arterial embolization for those who delivered vaginally and by cesarean. The risk of an invasive procedure remained significantly lower in the pilot network for women who delivered vaginally (adjusted odds ratio, 0.14; 95 percent confidence interval, 0.08 to 0.27), but not for women who delivered by cesarean section (adjusted odds ratio, 1.19; 95 percent confidence interval, 0.87 to 1.61), after the researchers controlled for potential confounding variables.

"Our results seem to confirm the association between intrauterine balloon tamponade and a significantly lower rate of invasive procedures among women undergoing vaginal delivery," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »